Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $45M (down 4.2% year over year) with net income of −$16M.
Q2 2026 key financials · XBRL
- Revenue
- $45M
- −4.2% YoY · −3.9% QoQ
- Net income
- −$16M
- +8.8% YoY · +11.6% QoQ
- Operating margin
- -33.0%
- Gross margin
- 78.5%
- EPS (diluted)
- −$0.24
- +14.3% YoY · +14.3% QoQ
Source: XBRL data from the TREACE MEDICAL CONCEPTS, INC. (TMCI) Q2 2026 10-Q on SEC EDGAR. USD.
TREACE MEDICAL CONCEPTS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $45.4M, down 4.2% YoY from $47.4M, including $3.1M lower stocking-distributor sales
- Gross margin 78.5% vs 79.7% YoY
- Operating loss $15.0M vs $17.0M YoY; net loss $15.9M vs $17.4M
- Cash and equivalents $12.6M plus marketable securities $33.0M at June 30, 2026
- Macro pressures, competition, lower-priced minimally invasive kits, and declining Lapiplasty sales expected to weigh on demand
Risk Factors
- No Risk Factors section provided in the filing excerpt
- Newly amended bylaws addressing SEC universal proxy Rule 14a-19 compliance
- Enhanced stockholder nomination disclosures and notice requirements
- Stockholder proxy solicitations now require non-white proxy cards
- 11,547 shares withheld at $2.23 per share for employee tax obligations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TREACE MEDICAL CONCEPTS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.